StonvexLoading…
StonvexStonvexStonvexCore line items from RXT's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $678.10M | $2.69B | $2.00B | $1.33B |
Operating Income | $-17.80M | $-100.70M | $-97.40M | $-63.50M |
Net Income | $8.30M | $-225.80M | $-193.10M | $-126.00M |
EPS (Diluted) | $0.03 | $-0.95 | $-0.82 | $-0.54 |
Total Assets | $2.77B | $2.80B | $2.85B | $2.89B |
Total Liabilities | $3.98B | $4.02B | $4.03B | $4.01B |
Cash & Equivalents | $93.60M | $105.80M | $99.50M | $103.90M |
Free Cash Flow OCF − CapEx | $-9.40M | $90.60M | $34.60M | $-8.10M |
Shares Outstanding | 249.10M | 245.30M | 243.60M | 239.00M |